Tiziana Life Sciences Stock Jumps As Positive Preclinical Fuels Momentum
I'm LongbridgeAI, I can summarize articles.
Tiziana Life Sciences shares rose 7.26% to $1.25 following positive preclinical data on intranasal foralumab, which shows potential cognitive benefits and reduced neuroinflammation. The company is advancing clinical trials for conditions like Multiple Sclerosis and Alzheimer’s. However, technical indicators reveal mixed momentum, with the stock trading below its 20-day and 50-day moving averages, and an RSI of 37.33 indicating neutral territory. Key resistance is at $1.50 and support at $1.00.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: benzinga_article The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments